$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta

$enta Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000119312513331068 Filed on August 12, 2013

Income Statement

Concept	2013 Q3	2013 Q2	2012 Q2
Revenue	$1.349M	$1.649M	$2.542M
YoY Change	-27.4%	-35.13%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.750M	$1.790M	$1.150M
YoY Change	-1.13%	55.65%
% of Gross Profit
Research & Development	$4.300M	$4.039M	$4.925M
YoY Change	0.94%	-17.99%
% of Gross Profit
Depreciation & Amortization	$70.00K	$60.00K	$30.00K
YoY Change	75.0%	100.0%	-92.11%
% of Gross Profit
Operating Expenses	$6.050M	$4.039M	$4.925M
YoY Change	0.33%	-17.99%
Operating Profit		-$4.178M	-$3.528M
YoY Change		18.42%
Interest Expense	$260.0K	$7.000K	$30.00K
YoY Change	116.67%	-76.67%
% of Operating Profit
Other Income/Expense, Net	$258.0K	$40.00K	$27.00K
YoY Change	486.36%	48.15%
Pretax Income	-$4.440M	-$4.138M	-$3.500M
YoY Change	9.63%	18.23%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$4.443M	-$4.138M	-$3.501M
YoY Change	9.65%	18.19%
Net Earnings / Revenue	-329.36%	-250.94%	-137.73%
Basic Earnings Per Share	-$0.25	-$0.23	-$4.31
Diluted Earnings Per Share	-$0.25	-$0.23	-$4.31
COMMON SHARES
Basic Shares Outstanding	17.91M shares	17.82M shares	1.120M shares
Diluted Shares Outstanding		17.82M shares	1.120M shares

Balance Sheet

Concept	2013 Q3	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$101.5M	$94.50M	$46.80M
YoY Change	131.74%	101.92%
Cash & Equivalents	$8.859M	$18.88M	$3.961M
Short-Term Investments	$92.60M	$75.70M	$42.80M
Other Short-Term Assets	$1.600M	$1.500M	$500.0K
YoY Change	166.67%	200.0%
Inventory
Prepaid Expenses
Receivables	$808.0K	$876.0K	$3.500M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$104.7M	$97.87M	$50.80M
YoY Change	121.34%	92.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.121M	$1.152M	$500.0K
YoY Change	83.47%	130.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$10.70M	$20.20M	$1.700M
YoY Change	529.41%	1088.24%
Other Assets	$400.0K	$400.0K	$1.300M
YoY Change	-81.4%	-69.23%
Total Long-Term Assets	$12.26M	$21.81M	$3.500M
YoY Change	152.58%	523.0%
TOTAL ASSETS
Total Short-Term Assets	$104.7M	$97.87M	$50.80M
Total Long-Term Assets	$12.26M	$21.81M	$3.500M
Total Assets	$117.0M	$119.7M	$54.30M
YoY Change	124.25%	120.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.481M	$918.0K	$800.0K
YoY Change	-19.99%	14.75%
Accrued Expenses	$3.035M	$2.023M	$3.100M
YoY Change	-21.5%	-34.74%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.526M	$2.941M	$3.900M
YoY Change	-21.07%	-24.59%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$359.0K	$535.0K	$2.700M
YoY Change	-27.91%	-80.19%
Total Long-Term Liabilities	$359.0K	$535.0K	$2.700M
YoY Change	-27.91%	-80.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.526M	$2.941M	$3.900M
Total Long-Term Liabilities	$359.0K	$535.0K	$2.700M
Total Liabilities	$6.505M	$5.260M	$6.600M
YoY Change	-20.99%	-20.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$107.5M	-$103.0M
YoY Change	-6.87%
Common Stock	$181.0K	$180.0K
YoY Change	1292.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.000K	$2.000K
YoY Change	0.0%
Treasury Stock Shares	208.8K shares	208.8K shares
Shareholders Equity	$110.5M	$114.4M	$47.70M
YoY Change
Total Liabilities & Shareholders Equity	$117.0M	$119.7M	$54.30M
YoY Change	124.25%	120.39%

Cashflow Statement

Concept	2013 Q3	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	-$4.443M	-$4.138M	-$3.501M
YoY Change	9.65%	18.19%
Depreciation, Depletion And Amortization	$70.00K	$60.00K	$30.00K
YoY Change	75.0%	100.0%	-92.11%
Cash From Operating Activities	-$2.510M	-$5.920M	-$3.820M
YoY Change	46.78%	54.97%	-113.81%
INVESTING ACTIVITIES
Capital Expenditures	-$210.0K	-$50.00K	-$50.00K
YoY Change	90.91%	0.0%	-82.14%
Acquisitions
YoY Change
Other Investing Activities	-$7.440M	-$48.16M	-$12.84M
YoY Change	-179.57%	275.08%	-40.72%
Cash From Investing Activities	-$7.640M	-$48.22M	-$12.88M
YoY Change	-182.68%	274.38%	-41.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	120.0K	-1.440M	-30.00K
YoY Change	-112.12%	4700.0%	-250.0%
NET CHANGE
Cash From Operating Activities	-2.510M	-5.920M	-3.820M
Cash From Investing Activities	-7.640M	-48.22M	-12.88M
Cash From Financing Activities	120.0K	-1.440M	-30.00K
Net Change In Cash	-10.03M	-55.58M	-16.73M
YoY Change	-253.36%	232.22%	-391.46%
FREE CASH FLOW
Cash From Operating Activities	-$2.510M	-$5.920M	-$3.820M
Capital Expenditures	-$210.0K	-$50.00K	-$50.00K
Free Cash Flow	-$2.300M	-$5.870M	-$3.770M
YoY Change	43.75%	55.7%	-113.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17911674	shares
CY2013Q1	us-gaap	Share Price SharePrice	14.00
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6837000
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3961000
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1689771	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.76
CY2012Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1134331	shares
CY2012Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1343147	shares
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.08
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1771471	shares
CY2012Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	70000000	shares
CY2012Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	436000
CY2012Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2151000
CY2012Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1656000
CY2012Q3	enta	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	1000
CY2012Q3	enta	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	11000
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17826060	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1245137	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18034876	shares
CY2013Q2	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1.00
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.89
CY2012Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	208816	shares
CY2012Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3866000
CY2012Q3	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	222000
CY2012Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	291000
CY2012Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1851000
CY2012Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	718000
CY2012Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5734000
CY2012Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	10000
CY2012Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1305000
CY2012Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	498000
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	-115353000
CY2012Q3	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	423000
CY2012Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115374000
CY2012Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	17000
CY2012Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1330000
CY2012Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2001000
CY2012Q3	us-gaap	Common Stock Value CommonStockValue	13000
CY2012Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	52162000
CY2012Q3	us-gaap	Liabilities Liabilities	8233000
CY2012Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2001000
CY2012Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q3	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	2001000
CY2012Q3	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	75000
CY2012Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	33251000
CY2012Q3	us-gaap	Assets Current AssetsCurrent	47308000
CY2012Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	34897000
CY2012Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	436000
CY2012Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	6471000
CY2012Q3	us-gaap	Assets Assets	52162000
CY2012Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	41378000
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10511000
CY2012Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1049000
CY2012Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	34907000
CY2012Q3	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	1893000
CY2012Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	604000
CY2012Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	19911000
CY2012Q3	us-gaap	Treasury Stock Value TreasuryStockValue	2000
CY2012Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	611000
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1503428	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.14
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	208816	shares
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2023000
CY2013Q2	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	247000
CY2013Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	437000
CY2013Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	217334000
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	918000
CY2013Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	370000
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2941000
CY2013Q2	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	436000
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-94000
CY2013Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	748000
CY2013Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	535000
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	114411000
CY2013Q2	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	421000
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103007000
CY2013Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	221000
CY2013Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1784000
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	180000
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	119671000
CY2013Q2	us-gaap	Liabilities Liabilities	5260000
CY2013Q2	us-gaap	Recorded Unconditional Purchase Obligation RecordedUnconditionalPurchaseObligation	668000
CY2013Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1784000
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	1784000
CY2013Q2	us-gaap	Accrued Rent Noncurrent AccruedRentNoncurrent	114000
CY2013Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	75668000
CY2013Q2	us-gaap	Assets Current AssetsCurrent	97866000
CY2013Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	95979000
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	436000
CY2013Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	20217000
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	436000
CY2013Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	16978000
CY2013Q2	us-gaap	Assets Assets	119671000
CY2013Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	112863000
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	20977000
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18878000
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	876000
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	19383000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-104000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	404000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-104000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4433000
CY2013Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	95885000
CY2013Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	981000
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1463000
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	21674000
CY2013Q2	us-gaap	Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue	20217000
CY2013Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1516000
CY2013Q2	us-gaap	Treasury Stock Value TreasuryStockValue	2000
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1152000
CY2013Q2	enta	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	98000
CY2013Q2	enta	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	4000
CY2013Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4600000	shares
CY2013Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	59892000
	dei	Entity Registrant Name EntityRegistrantName	ENANTA PHARMACEUTICALS INC
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001177648
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0103	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	2.59
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2864	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7052989	shares
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7052989	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.73	pure
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	356018	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M2D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	14.11
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	13156000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.01
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y7M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y6M
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	434854	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of Estimates</b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, management’s judgments of separate units of accounting and best estimate of selling price of those units of accounting within its revenue arrangements; the valuation of common stock, warrants and stock-based awards; the useful lives of property and equipment; and the accounting for income taxes, including uncertain tax positions and the valuation of net deferred tax assets. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company’s estimates.</font></p> </div>
	us-gaap	Revenues Revenues	30704000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	291000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	13966000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	100253000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2126000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	146000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-22000
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	217000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2126000
	us-gaap	Operating Income Loss OperatingIncomeLoss	13730000
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-912000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	100000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3540000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-173000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	340000
	us-gaap	Net Income Loss NetIncomeLoss	14070000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-697000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	77000
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-11000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.52
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2436637	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.78	pure
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1360644	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.68
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	56789000
	us-gaap	Maintenance Costs MaintenanceCosts	105000
	us-gaap	Paid In Kind Interest PaidInKindInterest	23000
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	161808000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-17000
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	2526000
	us-gaap	Share Based Compensation ShareBasedCompensation	777000
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	16974000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	148000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8367000
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	2454000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1288000
	us-gaap	Interest Expense InterestExpense	23000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-620000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	37000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-61578000
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	59892000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12541000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	437000
	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	13670000
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	711000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	36625000
	enta	Office Leases Expire OfficeLeasesExpire	September 2018
	enta	Onetime License Costs OnetimeLicenseCosts	50000
	enta	Undistributed Earnings Allocated To Participating Securities Diluted UndistributedEarningsAllocatedToParticipatingSecuritiesDiluted	13670000
	enta	Payout Percentage PayoutPercentage	1.00	pure
	enta	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
	enta	Premium On Marketable Securities PremiumOnMarketableSecurities	1170000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0090	pure
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	24325000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1075993	shares
	us-gaap	Revenues Revenues	39848000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	159000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	25437000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	46248000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1810000
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	837000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	3703000
	us-gaap	Operating Income Loss OperatingIncomeLoss	25385000
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	1516000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	63000
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	44000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1712000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	66000
	us-gaap	Net Income Loss NetIncomeLoss	25451000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-361000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-14000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	141000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-1140000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-14000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3603000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	82000
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	4035000
	us-gaap	Share Based Compensation ShareBasedCompensation	181000
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	14463000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	133000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2876000
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	14050000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1001000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-65000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	702000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	66000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27283000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10860000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	126000
	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	19606000
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	711000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	3850000
	enta	Undistributed Earnings Allocated To Participating Securities Diluted UndistributedEarningsAllocatedToParticipatingSecuritiesDiluted	17713000
CY2013Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.232	pure
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M6D
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0091	pure
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.31
CY2012Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1120400	shares
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.77	pure
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.31
CY2012Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M1D
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2012Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1120400	shares
CY2013Q2	enta	Milestone Payments Maximum Amount MilestonePaymentsMaximumAmount	5000000
CY2013Q2	enta	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
CY2013Q2	enta	Loss Contingency License Agreement Payment LossContingencyLicenseAgreementPayment	500000
CY2012Q2	us-gaap	Revenues Revenues	2542000
CY2012Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3501000
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4831000
CY2012Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	48000
CY2012Q2	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-21000
CY2012Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4831000
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3528000
CY2012Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	27000
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-3501000
CY2012Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1145000
CY2012Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1330000
CY2012Q2	us-gaap	Share Based Compensation ShareBasedCompensation	95000
CY2012Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	6070000
CY2012Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2012Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4925000
CY2012Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	237000
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0116	pure
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17819813	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.77	pure
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17819813	shares
CY2013Q2	us-gaap	Revenues Revenues	1649000
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4225000
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4138000
CY2013Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	64000
CY2013Q2	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-17000
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4138000
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4178000
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	40000
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-4138000
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-87000
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-87000
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1788000
CY2013Q2	us-gaap	Share Based Compensation ShareBasedCompensation	239000
CY2013Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5827000
CY2013Q2	us-gaap	Interest Expense InterestExpense	7000
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4039000
CY2013Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	237000

Files In Submission

Name	View Source	Status
0001193125-13-331068-index-headers.html	Edgar Link	pending
0001193125-13-331068-index.html	Edgar Link	pending
0001193125-13-331068.txt	Edgar Link	pending
0001193125-13-331068-xbrl.zip	Edgar Link	pending
d541104d10q.htm	Edgar Link	pending
d541104dex311.htm	Edgar Link	pending
d541104dex312.htm	Edgar Link	pending
d541104dex321.htm	Edgar Link	pending
enta-20130630.xml	Edgar Link	completed
enta-20130630.xsd	Edgar Link	pending
enta-20130630_cal.xml	Edgar Link	unprocessable
enta-20130630_def.xml	Edgar Link	unprocessable
enta-20130630_lab.xml	Edgar Link	unprocessable
enta-20130630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g541104g10p51.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R37.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R38.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R39.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta

2013 Q3 Form 10-Q Financial Statement

#000119312513331068 Filed on August 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENTA ENANTA PHARMACEUTICALS INC Stock $enta

2013 Q3 Form 10-Q Financial Statement

#000119312513331068 Filed on August 12, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENTA
ENANTA PHARMACEUTICALS INC Stock $enta